Please assess the completion status of the following clinical trial:

Trial Title: Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Capecitabine Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any adult patient starting capecitabine-containing chemotherapy~* Has never had capecitabine before~* Performance status 0-2 using the ECOG classification~* Life expectancy more than 6 months~* Agreed to stop any vitamin supplements, apart from vitamin D.~* Liver function studies including AST/ALT within 3x upper limit of normal~* Signed informed consent must be obtained from participating individuals

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- vitamin B6 (Type: EXPERIMENTAL): patient receiving xeloda and vitamin B6
- 2 placebo (Type: PLACEBO_COMPARATOR): patient receiving xeloda and placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).